Skip to Main Content

Roy H. Decker, MD/PhD

Professor of Therapeutic Radiology; Vice Chair for Clinical Research, Therapeutic Radiology; Director of the Clinical Trials Office, Yale Cancer Center; Associate Cancer Center Director, Clinical Sciences; Disease Aligned Research Team Leader, Therapeutic Radiology, Yale Cancer Center; Associate Director, Residency Training Program, Therapeutic Radiology

Contact Information

Roy H. Decker, MD/PhD

Office Location

Mailing Address

  • Therapeutic Radiology

    PO Box 208040

    New Haven, CT, 06520-8040

    United States

Research Summary

I am a radiation oncologist focusing on the treatment of lung cancer and head and neck cancer, working at the Yale University School of Medicine, and the Smilow Cancer Hospital at Yale New Haven. I am a member of the Cancer Center’s Radiobiology & Radiotherapy Program. For early lung cancer, my research focus is based on the treatment of stage I or II NSCLC with SBRT. For advanced cancer, my research focus has been the addition of targeted agents concurrently with fractionated radiation, in an effort to increase the tumor radiation response, and in combining radiation with immunotherapy in metastatic disease.

Research Interests

Carcinoma, Non-Small-Cell Lung; Lung; Medical Oncology; Neoplasm Metastasis; Radiotherapy

Clinical Trials

ConditionsStudy Title
LungMRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
LungPhase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Urinary BladderPhase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)
PancreasPhase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
LungA Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
Esophagus; Larynx; Lip, Oral Cavity and PharynxRandomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Breast - Female; BreastTAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Larynx; Lip, Oral Cavity and PharynxSingle-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
Larynx; Lip, Oral Cavity and PharynxPhase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Larynx; Lip, Oral Cavity and PharynxRadiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer
Lip, Oral Cavity and PharynxIndividualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA